Train drivers vote to increase strike motion

Pfizer has dropped its plans for a twice-daily weight-loss tablet after trials confirmed it brought about vital unwanted side effects.

The halt of its improvement is a blow to the drugmaker’s hopes of capitalising on the clamour for weight problems therapies in gentle of the success of Wegovy, developed by Danish rival Novo Nordisk.

Pfizer shares fell 5.9pc after markets opened on Wall Street after greater than half of the members in its scientific trial for the brand new drug dropped out over its unwanted side effects.

The firm had mentioned final yr that its oral weight problems tablets may generate greater than $10bn (£7.9bn) in future revenues.

It ended the trial of danuglipron after members within the trial reported gastrointestinal unwanted side effects, with many reporting nausea, vomiting and diarrhea.

Read the most recent updates beneath.